Valley National Advisers’s Viking Therapeutics VKTX Stock Holding History

Valley National Advisers’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.7K	Hold	350	–	–	﹤0.01%	576
2026 Q1	$11K	Hold	350	–	–	﹤0.01%	594
2025 Q4	$12K	Hold	350	–	–	﹤0.01%	579
2025 Q3	$9K	Hold	350	–	–	﹤0.01%	594
2025 Q2	$9K	Hold	350	–	–	﹤0.01%	592
2025 Q1	$8K	Hold	350	–	–	﹤0.01%	598
2024 Q4	$14K	Hold	350	–	–	﹤0.01%	505
2024 Q3	$22K	Hold	350	–	–	﹤0.01%	436
2024 Q2	$18K	Buy	+350	New	+$22.9K	﹤0.01%	522

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Valley National Advisers's VKTX Position: Q2 2026 in Review

Valley National Advisers held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 350 shares worth $13.7K. The position accounts for ﹤0.01% of the portfolio, ranked #576.

Valley National Advisers first reported a position in VKTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $22K in Q3 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Valley National Advisers held 350 shares of Viking Therapeutics worth $13.7K as of Q2 2026.
Valley National Advisers left its Viking Therapeutics share count unchanged in Q2 2026.
Viking Therapeutics made up ﹤0.01% of Valley National Advisers's portfolio in Q2 2026, its #576 holding.
Valley National Advisers first reported a position in Viking Therapeutics in Q2 2024 and has held it in 9 quarters since.
Valley National Advisers's Viking Therapeutics position peaked at $22K in Q3 2024.
432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Valley National Advisers's 13F filing for Q2 2026, filed 29 Jul 2026.